Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and Gemox Regimen for Transformational Treatment of Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Next Previous
X
Search
Trial Profile

A Single-arm, Open, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and Gemox Regimen for Transformational Treatment of Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
  • Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Sep 2022 Results(As of 27 April 2022) assessing efficacy and safety of tislelizumab combined with lenvatinib and GMOX in potentially resectable advanced BTC.presented at the 47th European Society for Medical Oncology Congress
    • 04 Sep 2022 Planned End Date changed from 30 Jan 2023 to 30 Dec 2023.
    • 04 Sep 2022 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top